{
  "abstract": "Purpose: Although indications for anti-interleukin 6 (IL-6) receptor antibody (anti-IL6R) therapy continue to expand, the clinical features of bloodstream infection (BSI) in anti-IL6R recipients remain poorly characterized. We investigated the prevalence, clinical and microbiological features of BSI among the anti-IL6R recipients.\n\nMethods: We conducted a multicenter, retrospective study of BSI episodes occurring within 90 days of anti-IL6R administration between 2005 and 2024. Complicated BSI was defined as the presence of either (1) infection-related mortality, (2) remote or localized suppurative complications, (3) embolic stroke, or (4) recurrence within 90 days. Associations between clinical variables and complicated BSI were analyzed.\n\nResults: Among 922 anti-IL6R recipients, 47 patients (5%) developed BSI. Demographics varied by indication for anti-IL6R, and 89% received concomitant immunosuppressive therapy. Catheter-related bloodstream (23%) and intra-abdominal (21%) were most common foci, followed by bone and joint (14%). At presentation, fever was absent in 53%, and serum CRP was within normal range in 30%. Septic shock occurred in 26%, and all-cause 30-day mortality was 19%. Complicated BSI occurred in 22 episodes (47%). In univariate analysis, underlying rheumatic disease, community acquisition, onset within 21 days of anti-IL6R administration, and Staphylococcus aureus or Klebsiella pneumoniae etiology were associated with complicated BSI, whereas higher pulse rate at presentation and Pitt bacteremia score ≥ 4 were inversely associated.\n\nConclusions: In anti-IL6R recipients, BSI frequently lacked typical signs such as fever but often resulted in severe outcomes. Clinicians should maintain a high index of suspicion for complicated BSI in this population.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan",
    "Department of Infection Control and Prevention, Kyoto University Hospital, 54 Shogoin- Kawahara-cho, Sakyo-ku, Kyoto, Japan",
    "Department of Infectious Diseases, Kyoto City Hospital, 1-2 Mibu-Higashi-Takada-cho, Nakagyo-ku, Kyoto, Japan",
    "Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan",
    "Department of Pharmacy, Kyoto City Hospital, 1-2 Mibu-Higashi-Takada-cho, Nakagyo- ku, Kyoto, Japan"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Koh Shinohara",
      "orcid": "0000-0001-8934-0375"
    },
    {
      "affs": [
        2
      ],
      "name": "Kentaro Tochitani",
      "orcid": "0000-0003-1588-5158"
    },
    {
      "affs": [
        1,
        3
      ],
      "name": "Yoshiki Katada",
      "orcid": "0000-0003-0803-8823"
    },
    {
      "affs": [
        4
      ],
      "name": "Tatsunori Murata"
    },
    {
      "affs": [
        4
      ],
      "name": "Mayu Morita"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Yusuke Tsuda"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Yasuhiro Tsuchido",
      "orcid": "0000-0003-1306-3652"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Masaki Yamamoto",
      "orcid": "0000-0002-7822-3269"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Yasufumi Matsumura",
      "orcid": "0000-0001-8595-8944"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Miki Nagao",
      "orcid": "0000-0002-8886-6145"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/amb226emst4sa.bib",
  "cited_by": 0,
  "doi": "10.1007/s15010-026-02938-0",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13727943/",
  "id": "amb226emst4sa",
  "issns": [
    "0300-8126",
    "1439-0973"
  ],
  "landing_url": "https://doi.org/10.1007/s15010-026-02938-0",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2730|Neutropenia and Cancer Infections"
    ]
  ],
  "openalex": "W7203716327",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s15010-026-02938-0.pdf",
  "pmcid": "PMC13727943",
  "pmid": "42611161",
  "published": "2026-08-18",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/amb226emst4sa.ris",
  "sources": [
    {
      "first_seen": "2026-11-06T12:23:43Z",
      "native_id": "PMC13727943",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s15010-026-02938-0"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Neutropenia and Cancer Infections",
      "subfield": "oncology"
    }
  ],
  "title": "Clinical characteristics of bloodstream infections in the patients receiving anti-IL-6 receptor antibody",
  "title_text": "Clinical characteristics of bloodstream infections in the patients receiving anti-IL-6 receptor antibody",
  "type": "peer-reviewed",
  "updated_at": "2026-11-07T12:21:02Z",
  "url": "https://research.draconitic.com/paper/amb226emst4sa",
  "venue": "Infection",
  "versions": []
}